U.S., Aug. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07778888) titled 'BL1107 Response and Intensity Guided Dosing for Hyperemia Resolution Trial' on Aug. 18.
Brief Summary: Trial RX01-BL1107-1202 is designed to identify the lowest effective concentration of BL1107 required for complete resolution of conjunctival hyperemia in participants with DED. Participants will be masked to concentration of BL1107 received.
Study Start Date: Oct., 2026
Study Type: INTERVENTIONAL
Condition:
Dry Eye Disease
Intervention:
DRUG: BL1107
BL1107 topical ocular solution
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Bausch & Lomb Incorporated
Disclaimer: Curated by HT Syndication....